Ziprasidone
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Ziprasidone: From Schizophrenia/Bipolar Disorder to Trichotillomania
One-Sentence Summary
Ziprasidone is an atypical (second-generation) antipsychotic internationally approved for schizophrenia and bipolar I disorder. The TxGNN model's top-ranked prediction for this drug is Trichotillomania (hair-pulling disorder), with a prediction score of 99.83%, but currently zero clinical trials and zero publications support this specific link — the evidence base is model-prediction-only (L5), and the recommended decision is Hold.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Schizophrenia / Bipolar I Disorder (acute manic or mixed episodes) — internationally approved indications (not found in this Evidence Pack; New Zealand licensing data is empty because the product is not marketed here) |
| Predicted New Indication | Trichotillomania |
| TxGNN Prediction Score | 99.83% |
| Evidence Level | L5 (model prediction only, no supporting studies) |
| New Zealand Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for ziprasidone is not available in this Evidence Pack (flagged as a High-severity data gap, DG002). Based on general pharmacological knowledge, ziprasidone is an atypical antipsychotic combining D2 dopamine receptor antagonism with 5-HT2A antagonism and 5-HT1A partial agonism — a serotonin–dopamine modulation profile that underlies its established efficacy in schizophrenia and bipolar disorder.
The TxGNN model links this serotonin–dopamine mechanism to trichotillomania on the theoretical basis that impulse-control disorders may involve similar dopaminergic/serotonergic dysregulation. However, the model's own rationale explicitly flags this as a weak and unvalidated mechanistic link: no clinical trial or published literature currently connects ziprasidone specifically to trichotillomania. This places the prediction at the lowest confidence tier (L5) — a graph-based inference rather than an evidence-backed hypothesis.
Important context: Among ziprasidone's other TxGNN-predicted indications in this Evidence Pack, "major affective disorder" (rank 3, score 99.66%) is far better supported — 29 clinical trials (including multiple completed Phase 2/3/4 RCTs) and 20 publications, rated L1 / Proceed with Guardrails. Several other ranked predictions (e.g., hydranencephaly, congenital disorder of glycosylation, X-linked myopia variants) appear to be low-confidence knowledge-graph noise with no plausible mechanistic connection to an antipsychotic's pharmacology. Decision-makers should weigh the full prediction list rather than relying on TxGNN rank alone.
Clinical Trial Evidence
Currently no related clinical trials registered for ziprasidone in trichotillomania.
Literature Evidence
Currently no related literature available for ziprasidone in trichotillomania.
New Zealand Market Information
Ziprasidone is currently not marketed in New Zealand — there are no Medsafe product authorizations on record (total_licenses = 0), so no product table can be produced.
Safety Considerations
Please refer to the package insert for safety information. (Key warnings, contraindications, and drug–drug interaction data for ziprasidone were not available in this Evidence Pack; Medsafe/TFDA package-insert retrieval is flagged as a Blocking data gap, DG001.)
Conclusion and Next Steps
Decision: Hold
Rationale: The top TxGNN-ranked prediction (trichotillomania) has no supporting clinical trials or literature and rests solely on a theoretical, unvalidated mechanistic hypothesis — insufficient to justify advancing this specific indication at this time.
To proceed, the following is needed:
- Preclinical or case-level evidence specifically linking ziprasidone to trichotillomania or related impulse-control disorders
- Resolution of the Blocking data gap: Medsafe/TFDA approved package insert (warnings and contraindications)
- Resolution of the High-severity data gap: confirmed mechanism-of-action documentation from DrugBank
- Given the disparity in evidence strength, consider prioritizing evaluation of major affective disorder (L1, 29 trials, 20 publications) as a more actionable repurposing candidate for this drug ahead of trichotillomania
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.